Highly Multiplexed Tests In The Making
This article was originally published in The Gray Sheet
Executive SummaryToday clinicians are left guessing which of dozens of organisms may have caused a respiratory infection, diarrhea or other illnesses, but developers of highly multiplexed assays see a future where they can take the guess work – and long delays – out of infectious disease diagnosis.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.